source
- Pierre Fabre aligns with FDA on resubmission of Ebvallo cell therapyPierre Fabre Laboratories announced that it has reached an agreement with the U.S. Food and Drug Administration on a new path for its cell therapy Ebvallo, which had been rejected twice. The FDA w…
- Neoadjuvant immunotherapy gaining favor for metastatic melanoma, says Dr. SznolDr. Mario Sznol discussed current guidance on using neoadjuvant therapy for patients with advanced melanoma. Patients who have active nodal disease detected by imaging or physical exam are now vie…